ANOVA

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Well, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, KKI, Neoplasm, Blood, ECOG, Cancer, ANOVA, Erythroderma, Female, Quality of life, Children's Oncology Group, Nursing, Medical imaging

Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • In multivariate analysis, worse HRQL was associated with being younger, female, moderate or severe pruritus and impaired function (as measured by ECOG PS).

New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life

Retrieved on: 
Monday, December 11, 2023
Well, American Society of Hematology, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, Neoplasm, TSE, Blood, ECOG, Cancer, ANOVA, Erythroderma, Society, Female, Quality of life, Children's Oncology Group, Kyowa Kirin, B-cell lymphoma

PRINCETON, N.J., Dec. 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analyzed baseline data collected prior to initiation of study treatments and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical," said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • Researchers concluded that assessing a patient's disease concerns may help guide treatment goals and therapeutic choice.

Dotmatics Launches GraphPad Prism 10 with a More Open File Format, Plus New Collaboration and Integration Capabilities

Retrieved on: 
Wednesday, November 15, 2023
Cloud, Research, Organization, GraphPad Software, Meta-analysis, Data analysis, CSV, Master of Science, Teaching, FAIR, Interdisciplinarity, MD, Epidemiology, PNG, ANOVA, Doctor of Philosophy, JSON, AI, Dotmatics, Publication, Collaboration, Telescopic sight, Medical device, Prism

BOSTON, Nov. 15, 2023 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced a major new release of its popular GraphPad Prism application, the world's leading analysis and graphing solution for scientific research. Prism 10 introduces a number of features including a new, more open file format (.prism), a variety of core graphing and analysis improvements, and a beta for Prism Cloud. The enhanced functionality makes it easier for scientists using Prism to collaborate and integrate diverse data into their scientific workflows and applications. Learn more about the new capabilities at: https://www.graphpad.com/updates/prism-1000-release-notes.

Key Points: 
  • Prism 10 introduces a number of features including a new, more open file format (.prism), a variety of core graphing and analysis improvements, and a beta for Prism Cloud.
  • Prism is an advanced statistical analysis software designed to help scientists create graphs to visualize and analyze data.
  • In February, Dotmatics announced that its R&D platform was the very first to integrate directly with Prism.
  • The new, more open Prism file format helps organizations connect scientific workflows that allow for greater collaboration and interdisciplinary research.

GMH Communities Expands Its Pioneering Innovative Living Vertical Tailored Toward Life Sciences, Tech and Healthcare Students and Professionals, ANOVA Aggie Square

Retrieved on: 
Thursday, October 12, 2023
Aggie, Partnership, Engineering, Student, UC, ANOVA, Innovation, Employment, University, University of California, Davis, Health, Creativity, CBRE, Environment, History, Research, Housing, GMH, Industrial design

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- GMH Communities (GMH), a vertically integrated real estate company, today announced the rapid expansion of its Innovative Living portfolio with the announcement of ANOVA Aggie Square, a mixed-use building designated for housing located on the University of California, Davis campus in Sacramento. ANOVA Aggie Square will create a unique live/learn/work/play environment to foster collaboration and creativity. GMH's Innovative Living brand ANOVA offers modern residential communities tailored to the needs of professionals and students in the budding life sciences, healthcare, and technology fields.

Key Points: 
  • GMH's Innovative Living brand ANOVA offers modern residential communities tailored to the needs of professionals and students in the budding life sciences, healthcare, and technology fields.
  • ANOVA Aggie Square will be completed as part of Aggie Square's first phase, currently under development by Wexford Science & Technology, LLC.
  • GMH has already completed its first Innovative Living development under the ANOVA name: ANOVA uCity Square in Philadelphia .
  • ANOVA Aggie Square is one of four "Innovative Living" developments GMH has under construction or in the immediate development pipeline.

Big or Small, Red or Blue – States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes

Retrieved on: 
Thursday, July 13, 2023
Alternative Medicine, White House, Federal Government, Healthcare Reform, Health, Public Policy, Foundation, Congressional News, Views, Government, Medical Supplies, Diabetes, Insurance, Human Resources, People with Disabilities, Professional Services, Philanthropy, Health Technology, Parenting, Health Insurance, Advocacy Group Opinion, Women, Telemedicine, Virtual Medicine, Seniors, Other Health, Men, Pharmaceutical, Optical, Family, Oncology, Mental Health, Medical Devices, Consumer, Hospitals, Practice Management, Physical Therapy, Fitness & Nutrition, Managed Care, Dental, General Health, Cardiology, Doctor of Pharmacy, Health insurance marketplace, Robert Wood Johnson Foundation, OOP, ANOVA, Silver, Platinum, Medicine, Pharmacy, MS, Advocacy, Headache, Gold, Affordable Care Act, ACA, Patient, DSM-IV codes, Outreach, PBM, Paps, Chronic condition, Care Act 2014, HIX, Rest, Disease, Conditional sentence, Legislation, Health insurance

In nineteen states, to date, these laws protect patient assistance programs (PAPs) by requiring that the financial assistance given to patients count toward their co-pays, deductibles, and out-of-pocket (OOP) maximums.

Key Points: 
  • In nineteen states, to date, these laws protect patient assistance programs (PAPs) by requiring that the financial assistance given to patients count toward their co-pays, deductibles, and out-of-pocket (OOP) maximums.
  • “Insurance companies assert that restricting accumulator and maximizer programs will cause higher health insurance premiums for everyone, but that claim is false.
  • The second variable analyzed was the introduction of legislation protecting patient assistance programs by prohibiting accumulators and/or maximizers.
  • The analysis shows that across all “metal tiers,” there has been no statistically significant difference in the rates of health insurance premium increases upon passage or implementation of legislation protecting patient assistance programs by prohibiting accumulator and/or maximizer policies.

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

Retrieved on: 
Thursday, July 13, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Survival rate, OTC Markets Group, PPCB, Pancreatic cancer, US Foods, MB, Life, Skin, Proprietary company, Neoplasm, Alternative medicine, Survival, EMT, ANOVA, Cancer, Breast, University, Toxicity, Brain, ResearchGate, Prostate, Teaching hospital, Lung, Death, National Cancer Institute, Bachelor of Medicine, Bachelor of Surgery, PRP, MD, Patient, BAS, Chymotrypsinogen, Scientific Reports, Trypsinogen, Kidney, Liver, Growth, MEI, Ovarian cancer, US FDA, Disease, Pharmaceutical industry, Nature

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.
  • The EMT is a mechanism by which cancerous cells become motile and invasive, as well as immortal, thus seeding new tumors.
  • We have published scientific and clinical data in peer reviewed journals providing evidence that PRP can become an effective tool in the fight against cancer.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (US FDA) for treatment of pancreatic cancer.

Global Healthy Living Foundation Launches Free Tool Demonstrating How State Laws Protecting Patient Assistance Programs Impact Health Insurance Premiums

Retrieved on: 
Tuesday, November 29, 2022
Technology, Insurance, Professional Services, Public Policy, Government, Health Insurance, Software, State, Local, Pharmaceutical, Health, Data Management, COVID-19, Affordable Care Act, Injury, Legislation, Conditional sentence, MS, Osteoporosis, Care Act 2014, OOP, Insurance, PBM, Social media, Caregiver, Policy, Patient, Cardiovascular disease, Education, Arthritis, HIX, Robert Wood Johnson Foundation, Platinum, Gold, Doctor of Pharmacy, Pharmacy, Health insurance marketplace, Rest, Family, Migraine, Quality of life, Psoriasis, ACA, ANOVA, 1946 Antarctica PBM Mariner crash, Vaccine, Silver, Inflammatory bowel disease, Health insurance

The Global Healthy Living Foundation (GHLF) today launched a free, interactive tool that will provide legislators, policy makers, and interested parties with objective data demonstrating how U.S. health insurance premiums have fluctuated since 2014.

Key Points: 
  • The Global Healthy Living Foundation (GHLF) today launched a free, interactive tool that will provide legislators, policy makers, and interested parties with objective data demonstrating how U.S. health insurance premiums have fluctuated since 2014.
  • Our analysis shows that the assertion made by insurance companies and PBMs that restricting accumulator and maximizer programs will cause higher health insurance premiums simply isnt true.
  • The second variable analyzed was the introduction of legislation protecting patient assistance programs by prohibiting accumulators and/or maximizers.
  • This tool will help stakeholders visualize health insurance premium changes year to year and, specifically, as related to restriction of accumulator and maximizer programs, said Louis Tharp, executive director and co-founder, Global Healthy Living Foundation.

OriginLab Releases New Data Analysis and Graphing Software, Origin 2023

Retrieved on: 
Tuesday, November 8, 2022
Software, Pharmacology, Ontario Fault Determination Rules, Physics, Worksheet, Tick, Engineering, CSV, Theme (computing), Chemistry, Explorers Program, Microsoft Excel, Government, Exploration, Note, Bootstrapping, University, Spline, 3D, Data analysis, Window, ANOVA, Automatic, Folder, NetCDF, Biology, Fortune Global 500, Multimedia, Video game console, Typesetting, Surveying, Industrial design, Graph, App

NORTHAMPTON, Mass., Nov. 8, 2022 /PRNewswire/ -- OriginLab, a leading publisher of data analysis and graphing software, today announced the release of Origin® and OriginPro® 2023. This latest version of OriginLab's award-winning software application adds 100+ new features and improvements, plus a suite of all-new Apps to extend Origin's graphing and analysis capabilities.

Key Points: 
  • This latest version of OriginLab's award-winning software application adds 100+ new features and improvements, plus a suite of all-new Apps to extend Origin's graphing and analysis capabilities.
  • Origin 2023 supports plotting Double-Y graphs in a single layer, allowing easier manipulation and analysis of plotted data.
  • Founded in 1992, OriginLab develops data analysis and graphing software for users in corporations, government agencies, colleges, and universities worldwide.
  • Its flagship products, Origin and OriginPro, provide a comprehensive solution for scientists and engineers at every technical level to analyze, graph, and professionally present data.

NEUROLENSES HAVE SIGNIFICANT IMPACT ON READING SPEED

Retrieved on: 
Monday, August 8, 2022
Headache, Industry, CEO, Population, Technology, Learning, Eye, Patient, Acceleration, Control, Neurology, Reading, Treatment, ANOVA, Tablet, Nelson–Denny Reading Test, Comprehension, OD, Optometry, SD, Phantom contour, Telescopic sight, Camera

COPPELL, Texas, Aug. 8, 2022 /PRNewswire/ -- As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and productivity improvement. In a parallel arm study evaluating reading speed at baseline, after seven days of lens wear the mean (±SD) improvement in reading speed with Neurolenses was almost 70% higher than the mean (±SD) improvement in reading speed with other premium lens designs.

Key Points: 
  • In a parallel arm study evaluating reading speed at baseline, after seven days of lens wear the mean (SD) improvement in reading speed with Neurolenses was almost 70% higher than the mean (SD) improvement in reading speed with other premium lens designs.
  • NEUROLENSES' SIGNIFICANT IMPACT ON READING SPEED.
  • The mean (SD) improvement in the reading speed for Neurolenses was +20.96 words per minute, and the mean (SD) improvement in the reading speed for the Control was +12.39 words per minute.
  • ANOVA analysis revealed a statistically significant improvement in the reading speed with Neurolenses compared to the Control lens (F = 4.45; p = 0.03).